阿斯利康(AZN.US)胃癌围手术期PD-L1联合疗法优于标准治疗

智通财经2025-03-07

智通财经APP获悉，3月7日，阿斯利康(AZN.US)宣布III期MATTERHORN研究结果显示，Imfinzi(度伐利尤单抗)联合标准治疗FLOT(氟尿嘧啶、亚叶酸钙、奥沙利铂和多西他赛)化疗作为可切除的早期和局部晚期(II期、III期、IVA期)的胃癌和胃食管交界处癌(GEJ)患者围手术期治疗方案，主要终点无事件生存期(EFS)具有统计学意义和临床意义的改善。MATTERHORN是首个证明...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2517438513?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-07 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517438513","market":"hk","top_or_hot":-1,"title":"阿斯利康(AZN.US)胃癌围手术期PD-L1联合疗法优于标准治疗","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，3月7日，阿斯利康(AZN.US)宣布III期MATTERHORN研究结果显示，Imfinzi(度伐利尤单抗)联合标准治疗FLOT(氟尿嘧啶、亚叶酸钙、奥沙利铂和多西他赛)化疗作为可切除的早期和局部晚期(II期、III期、IVA期)的胃癌和胃食管交界处癌(GEJ)患者围手术期治疗方案，主要终点无事件生存期(EFS)具有统计学意义和临床意义的改善。MATTERHORN是首个证明...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1259345.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阿斯利康(AZN.US)胃癌围手术期PD-L1联合疗法优于标准治疗</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阿斯利康(AZN.US)胃癌围手术期PD-L1联合疗法优于标准治疗\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-07 21:20 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1259345.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，3月7日，阿斯利康(AZN.US)宣布III期MATTERHORN研究结果显示，Imfinzi(度伐利尤单抗)联合标准治疗FLOT(氟尿嘧啶、亚叶酸钙、奥沙利铂和多西他赛)化疗作为可切除的早期和局部晚期(II期、III期、IVA期)的胃癌和胃食管交界处癌(GEJ)患者围手术期治疗方案，主要终点无事件生存期(EFS)具有统计学意义和临床意义的改善。MATTERHORN是首个证明...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1259345.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PD","symbol_name":"PagerDuty, Inc.","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1259345.html","article_id":"2517438513","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517438513","pubTimestamp":1741353606,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，3月7日，阿斯利康宣布III期MATTERHORN研究结果显示，Imfinzi联合标准治疗FLOT化疗作为可切除的早期和局部晚期的胃癌和胃食管交界处癌患者围手术期治疗方案，主要终点无事件生存期具有统计学意义和临床意义的改善。MATTERHORN是首个证明免疫疗法联合治疗优于标准治疗的全球随机III期临床研究。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"PD":"PagerDuty, Inc.","BK4023":"应用软件","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4007":"制药","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","AZN":"阿斯利康","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4588":"碎股","BK4568":"美国抗疫概念","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4585":"ETF&股票定投概念","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC"},"translate_title":"AstraZeneca (AZN.US) Perioperative PD-L1 combination therapy for gastric cancer is superior to standard care","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PD":1,"AZN":1},"content_text":"智通财经APP获悉，3月7日，阿斯利康(AZN.US)宣布III期MATTERHORN研究结果显示，Imfinzi(度伐利尤单抗)联合标准治疗FLOT(氟尿嘧啶、亚叶酸钙、奥沙利铂和多西他赛)化疗作为可切除的早期和局部晚期(II期、III期、IVA期)的胃癌和胃食管交界处癌(GEJ)患者围手术期治疗方案，主要终点无事件生存期(EFS)具有统计学意义和临床意义的改善。MATTERHORN是首个证明免疫疗法联合治疗优于标准治疗的全球随机III期临床研究。纽约纪念斯隆凯特琳癌症中心的胃肠肿瘤服务部的首席主治医师Yelena Y Janjigian博士(该试验的主要研究者)表示：“尽管接受了以治愈为目的的化疗和手术，胃癌患者仍经常面临癌症复发以及预后不良的风险。MATTERHORN数据表明，包含度伐利尤单抗的围手术期联合治疗方案在临床意义上改善了患者结局，其中包括降低癌症复发的风险。”阿斯利康的首席医学官兼肿瘤学首席开发官Cristian Massacesi表示：“MATTERHORN是首个在可切除的胃癌和胃食管交界处癌患者中显示出无进展生存期统计学显著改善的免疫疗法III期临床研究。这种围手术期使用Imfinzi的方法强调了我们介入癌症早期阶段进行治疗的承诺，这能够对患者的生命产生最大的影响和帮助。”","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2517438513","isCrawlerRequest":true}